# Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients

> **NCT00412243** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 51 (actual)

## Conditions studied

- Burkitt's Lymphoma
- Lymphoblastic Lymphoma
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00412243
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2013-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412243, "Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00412243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*